Plant Name: Amomum xanthioides
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; | |
| TSHR; | |
| ALPI; P4HB; ADK; AKR1B1; POLB; | |
| GAA; | |
| MAPK1; | |
| CA2; CA1; CA12; CA7; CA4; | |
| PPARA; PPARD; | |
| TLR2; | |
| STAT6; | |
| SLC28A2; SLC28A1; SLC28A3; | |
| HTT; RAB9A; LMNA; NPC1; FABP3; FABP5; FABP2; FABP4; MAPT; | |
| XDH; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.635E-11 | 7.224E-07 | CA1, CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.084E-09 | 2.200E-05 | CA1, CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.302E-08 | 5.570E-05 | CA1, CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.563E-07 | 2.128E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 2.445E-07 | 2.315E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 5.852E-07 | 4.248E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 6.359E-07 | 4.467E-04 | ADORA1, CYP1A1, LMNA, P4HB, PPARA, PPARD, TLR2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.349E-07 | 5.509E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 9.293E-07 | 5.952E-04 | ADORA2A, AKR1B1, CYP1A1, CYP1B1, MAPK1, POLB, STAT6, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 1.103E-06 | 6.489E-04 | ADORA2A, AKR1B1, CYP1A1, CYP1B1, FABP3, MAPK1, NPC1, POLB, STAT6, TLR2 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.982E-06 | 1.053E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 2.175E-06 | 1.127E-03 | ADORA1, ADORA2A, AKR1B1, CA2, CYP1A1, CYP1A2, CYP1B1, FABP5, GAA, HTT, LMNA, MAPK1, POLB, PPARA, PPARD, SMN1, SMN2, TLR2, TSHR |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 3.769E-06 | 1.616E-03 | SLC28A2, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 3.769E-06 | 1.616E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 3.769E-06 | 1.616E-03 | SLC28A2, SLC28A3 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 3.865E-06 | 1.618E-03 | ADORA1, ADORA2A, MAPT |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.846E-06 | 1.991E-03 | ADORA2A, CA2, CA7, HTT, MAPK1, NPC1 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 6.802E-06 | 2.743E-03 | ADORA1, ADORA2A, ADORA3, CYP1B1, FABP3, LMNA, PPARD, TLR2, XDH |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 8.062E-06 | 3.080E-03 | AKR1B1, CYP1A1, CYP1A2, CYP1B1, NPC1, PPARD |
| BP | GO:0007610; behavior | GO:0007610; behavior | 8.268E-06 | 3.104E-03 | ADORA2A, GAA, HTT, MAPK1, MAPT, NPC1, PPARA, TLR2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.116E-06 | 3.309E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.129E-05 | 3.670E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.129E-05 | 3.670E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.129E-05 | 3.670E-03 | SLC28A1, SLC28A3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.129E-05 | 3.670E-03 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.211E-05 | 3.821E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.211E-05 | 3.821E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006631; fatty acid metabolic process | 2.249E-05 | 5.989E-03 | CYP1A1, CYP1A2, CYP1B1, FABP3, PPARA, PPARD |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.256E-05 | 5.989E-03 | CYP1A1, CYP1A2 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.392E-05 | 8.375E-03 | ADORA1, ADORA2A, CA2, CA7, HTT, MAPK1, NPC1 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 3.512E-05 | 8.496E-03 | AKR1B1, CA2, CYP1A2, FABP3, NPC1, PPARA, TLR2, TSHR |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.146E-10 | 1.651E-08 | CA12; CA1; CA2; CA4; CA7 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.417E-09 | 2.460E-07 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.565E-05 | 1.283E-03 | ADORA2A; ADORA1; MAPK1; PPARA; TSHR |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 5.956E-05 | 1.715E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.636E-04 | 3.737E-03 | FABP4; ADORA1; TSHR |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.817E-04 | 3.737E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.591E-04 | 6.463E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.053E-04 | 8.084E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.835E-03 | 2.033E-02 | ADORA2A; ADORA3; ADORA1; TSHR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.525E-03 | 1.830E-02 | ADORA3; ADORA1; MAPK1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.503E-05 | 1.283E-03 | CYP1A2; XDH |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.666E-03 | 2.742E-02 | MAPK1; STAT6; TLR2 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 3.893E-03 | 3.659E-02 | ADORA3; ADORA1; MAPK1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.066E-03 | 3.659E-02 | CYP1A1; CYP1B1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 5.253E-03 | 4.449E-02 | MAPK1; PPARD |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.479E-03 | 1.830E-02 | GAA; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 8.672E-04 | 1.249E-02 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; CA1; MAPK1; TLR2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; AKR1B1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA2A; ADORA1; CA1; CA1; AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA2A; ADORA1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; ADK |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; XDH |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA2A; ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PPARD |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |